Literature DB >> 3760186

Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

S Lopez-Hilker, T Galceran, Y L Chan, N Rapp, K J Martin, E Slatopolsky.   

Abstract

Hypocalcemia is the main factor responsible for the genesis of secondary hyperparathyroidism in chronic renal disease. Studies with parathyroid cells obtained from uremic patients indicate that there is a shift in the set point for calcium-regulated hormone (parathyroid hormone [PTH] secretion. Studies were performed in dogs to further clarify this new potential mechanism. Hypocalcemia was prevented in uremic dogs by the administration of a high calcium diet. Initially, ionized calcium was 4.79 +/- 0.09 mg/dl and gradually increased up to 5.30 +/- 0.05 mg/dl. Despite a moderate increase in ionized calcium, immunoreactive PTH (iPTH) increased from 64 +/- 7.7 to 118 +/- 21 pg/ml. Serum 1,25(OH)2D3 decreased from 25.4 +/- 3.8 to 12.2 +/- 3.6 pg/ml. Further studies were performed in two other groups of dogs. One group received 150-200 ng and the second group 75-100 ng of 1,25(OH)2D3 twice daily. The levels of 1,25(OH)2D3 increased from 32.8 +/- 3.5 to a maximum of 69.6 +/- 4.4 pg/ml. In the second group the levels of serum 1,25(OH)2D3 after nephrectomy remained normal during the study. Amino-terminal iPTH did not increase in either of the two groups treated with 1,25(OH)2D3. In summary, the dogs at no time developed hypocalcemia; however, there was an 84% increase in iPTH levels, suggesting that hypocalcemia, per se, may not be the only factor responsible for the genesis of secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3760186      PMCID: PMC423770          DOI: 10.1172/JCI112666

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3.

Authors:  S G Massry; R Stein; J Garty; A I Arieff; J W Coburn; A W Norman; R M Friedler
Journal:  Kidney Int       Date:  1976-06       Impact factor: 10.612

2.  Unique biosynthesis by kidney of a biological active vitamin D metabolite.

Authors:  D R Fraser; E Kodicek
Journal:  Nature       Date:  1970-11-21       Impact factor: 49.962

Review 3.  Intestinal absorption of calcium and the effect of renal insufficiency.

Authors:  J W Coburn; D L Hartenbower; S G Massry
Journal:  Kidney Int       Date:  1973-08       Impact factor: 10.612

4.  Hypercalcemia and hypophosphatemia in ponies following bilateral nephrectomy.

Authors:  B Tennant; J E Lowe; J B Tasker
Journal:  Proc Soc Exp Biol Med       Date:  1981-07

5.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

6.  Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells.

Authors:  J Silver; J Russell; L M Sherwood
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

7.  Vitamin D metabolite-binding proteins in human tissue.

Authors:  J G Haddad; J Walgate; C Min; T J Hahn
Journal:  Biochim Biophys Acta       Date:  1976-10-22

8.  Hypercalcemia after nephrectomy in the dog: role of the kidneys and parathyroid glands.

Authors:  S N Tuma; L E Mallette
Journal:  J Lab Clin Med       Date:  1983-08

9.  On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.

Authors:  E Slatopolsky; S Caglar; J P Pennell; D D Taggart; J M Canterbury; E Reiss; N S Bricker
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

10.  Suppressive effect of 1,25-dihydroxyvitamin D3 on circulating parathyroid hormone in acute renal failure.

Authors:  S Madsen; K Olgaard; J Ladefoged
Journal:  J Clin Endocrinol Metab       Date:  1981-10       Impact factor: 5.958

View more
  13 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 2.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

Review 3.  Vitamin D and analogues in renal bone disease and implications for osteoporosis.

Authors:  J A Kanis; E V McCloskey; M N Beneton
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

4.  Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients.

Authors:  M Wallot; K E Bonzel; A Winter; B Geörger; B Lettgen; M Bald
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

5.  Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat.

Authors:  T Naveh-Many; J Silver
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Efficacy of calcium carbonate and low-dose vitamin D/1,25(OH)2D3 in reducing the risk of developing renal osteodystrophy in children on continuous ambulatory peritoneal dialysis.

Authors:  H Jüppner; P F Hoyer; K Latta; L Winkler; G Offner; J Brodehl
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

7.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

Authors:  J A Delmez; C Tindira; P Grooms; A Dusso; D W Windus; E Slatopolsky
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

Review 8.  Calcitriol administration in end-stage renal disease: intravenous or oral?

Authors:  L D Quarles; O S Indridason
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

9.  Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia.

Authors:  H Funahashi; Y Tanaka; T Imai; M Wada; K Tsukamura; Y Hayakawa; N Matsuura; T Kikumori; M Oiwa; Y Tominaga; H Takagi
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

10.  Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.

Authors:  N A Hamdy; J A Kanis; M N Beneton; C B Brown; J R Juttmann; J G Jordans; S Josse; A Meyrier; R L Lins; I T Fairey
Journal:  BMJ       Date:  1995-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.